Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts
Abstract
Predicting antidepressant response remains a major challenge, and it is unclear whether reported polygenic associations reflect drug-specific non-response or a broader propensity for treatment modification. We analysed participants with at least one antidepressant monotherapy episode of ≥28 days in the All of Us (AoU; n=98,357) and Pharmlines (Lifelines linked to IADB.nl; n=12,884) cohorts, comparing continuation with switching, discontinuation and augmentation (atypical antipsychotic or lithium) in relation to polygenic scores (PGS). Among individuals with recorded depression, switching, but not discontinuation, was associated with anxiety, higher depression symptom count and stress-related measures in both cohorts. Depression PGS was associated with switching in AoU (OR=1.16 per SD, 95% CI 1.12–1.20), with a concordant nominally significant estimate in Pharmlines (OR=1.11, 1.01–1.22). In AoU, depression PGS showed the strongest association with being in a higher treatment-intensity category (continuation < switching < augmentation; ordinal OR=1.18 per SD, 95% CI 1.15–1.21), whereas schizophrenia and bipolar disorder PGS were selectively associated with augmentation. There was no evidence that PGS associations with switching differed across antidepressant classes. Familial aggregation in Pharmlines was detectable for continuation, including SSRI and SNRI continuation, but not for switching or discontinuation. Antidepressant switching was associated with greater depression…
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.